『Season 4 - Ep.9: Heart Failure 2026 Special - Biomarkers in heart failure - Digoxin in HFrEF - Heart Failure 2026 Scientific Highlights』のカバーアート

Season 4 - Ep.9: Heart Failure 2026 Special - Biomarkers in heart failure - Digoxin in HFrEF - Heart Failure 2026 Scientific Highlights

Season 4 - Ep.9: Heart Failure 2026 Special - Biomarkers in heart failure - Digoxin in HFrEF - Heart Failure 2026 Scientific Highlights

無料で聴く

ポッドキャストの詳細を見る

This episode covers:

  • Cardiology This Week: A concise summary of recent studies
  • Biomarkers in heart failure
  • Digoxin in HFrEF
  • Scientific Highlights from Heart Failure 2026

Host: Wilfried Mullens

Guests: Lynne Stevenson, Dirk van Veldhuisen, Theresa McDonagh

Want to watch that episode? Go to: https://esc365.escardio.org/event/2565

Disclaimer:

ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. A

ny views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.

The ESC is not liable for any translated content of this video. The English language always prevails.

ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.

Declarations of interests:

Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Dirk van Veldhuisen and Lynne Warner Stevenson have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris.

John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report:Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Theresa McDonagh has declared to have potential conflicts of interest to report: honoraria from Boeringer Ingelheim.

Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

adbl_web_anon_alc_button_suppression_c
まだレビューはありません